PGNY vs. SHC, AGL, OTRK, FMS, DVA, JANX, IDYA, PRCT, ARWR, and TXG
Should you be buying Progyny stock or one of its competitors? The main competitors of Progyny include Sotera Health (SHC), agilon health (AGL), Ontrak (OTRK), Fresenius Medical Care (FMS), DaVita (DVA), Janux Therapeutics (JANX), IDEAYA Biosciences (IDYA), PROCEPT BioRobotics (PRCT), Arrowhead Pharmaceuticals (ARWR), and 10x Genomics (TXG). These companies are all part of the "medical" sector.
Progyny (NASDAQ:PGNY) and Sotera Health (NASDAQ:SHC) are both mid-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, community ranking, media sentiment, valuation, profitability and risk.
In the previous week, Progyny had 26 more articles in the media than Sotera Health. MarketBeat recorded 28 mentions for Progyny and 2 mentions for Sotera Health. Sotera Health's average media sentiment score of 1.79 beat Progyny's score of 0.15 indicating that Sotera Health is being referred to more favorably in the news media.
94.9% of Progyny shares are owned by institutional investors. Comparatively, 91.0% of Sotera Health shares are owned by institutional investors. 12.3% of Progyny shares are owned by company insiders. Comparatively, 55.1% of Sotera Health shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Progyny currently has a consensus price target of $46.11, suggesting a potential upside of 67.49%. Sotera Health has a consensus price target of $17.70, suggesting a potential upside of 60.33%. Given Progyny's stronger consensus rating and higher probable upside, analysts plainly believe Progyny is more favorable than Sotera Health.
Progyny has a beta of 1.51, suggesting that its share price is 51% more volatile than the S&P 500. Comparatively, Sotera Health has a beta of 2.08, suggesting that its share price is 108% more volatile than the S&P 500.
Progyny has higher revenue and earnings than Sotera Health. Progyny is trading at a lower price-to-earnings ratio than Sotera Health, indicating that it is currently the more affordable of the two stocks.
Progyny has a net margin of 5.53% compared to Sotera Health's net margin of 5.09%. Sotera Health's return on equity of 48.47% beat Progyny's return on equity.
Progyny received 39 more outperform votes than Sotera Health when rated by MarketBeat users. Likewise, 74.34% of users gave Progyny an outperform vote while only 56.96% of users gave Sotera Health an outperform vote.
Summary
Progyny beats Sotera Health on 12 of the 18 factors compared between the two stocks.
Get Progyny News Delivered to You Automatically
Sign up to receive the latest news and ratings for PGNY and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PGNY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
